Carregar apresentação
A apresentação está carregando. Por favor, espere
Publicoufabian fabian Alterado mais de 7 anos atrás
1
Drug Formulations Oral Formulations: Tablet, Capsule, Solution, Suspension, etc. Parenterals: Injections, Ophthalmics Inhalations Topicals
2
Dosage Forms Containing Solid API Tablet Capsule Ointment Suppository Suspension Oral Injection Inhalation Ophthalmic
3
Tablet Disintegration Dissolution Absorption
4
Particle Size Crystal Form Dissolution Tableting Properties Physical and Chemical Stability Solubility Important Solid-State Properties
5
Problems in Dosage forms Resulting from Use of the Wrong Polymorph Suspension (Aqueous vehicle) - Crystal growth leading to undesirableparticle size distribution, particularly, in parenteral suspensions, or caking Cream - Crystal growth, yielding gritty, cosmetically unacceptable creams ore uneven distribution of active ingredient Solution - Precipitation due to crystal growth Suppositories - Melting point changes of vehicles resulting in softening of product or hindrance in release of active ingredient
6
Chemical Stability Summary of the reactives of the α, β and γcrystalline forms of ethoxycinnamic acid exposure to ultraviolet light
7
Bioavailability Comparison of mean blood serum levels obtained with choramphenical palmitate suspension containing varying ratios of A and B polymorphs (per cent of Form B in the suspension: M, 0%; N 25%; O, 50%, P; 75%; L, 100%)
8
Tablet Friability: 30 tabs, wt loss < 1% Disintegration Dissolution Rate or Dissolution Profile Uniformity of Dosage Unit Weight Variation: 10 units Content Uniformity: 10 units Quality Control of Tablets
9
Tablet Formulation Filler: Starch, Lactose, Mannitol Microcrystalline Cellulose (Avecil) Binder: Starch, Acacia, Gelatin, Simple Syrup Lubricant: Mg Stearate, Ca Stearate, Talc Disintegrant: Starch, Avecil Flavor Colorant: D&C Misc. : Stabilizer
10
Pediatric Chewable Aspirin Tablet (wet granulation) Aspirin Mannitol Saccharin sodium Acacia Starch Stearic acid Talc Dry Flavor 100.0 115.0 1.0 4.0 20.0 0.5 8.0 1.5 250 mg/tab
11
Tablet Manufacturing (Wet Granulation) Binder Preparation (10% Acacia) Sieving (Mannitol & Saccharin sodium) Mixing & Granulation Sieving (Aspirin, starch, Stearic acid, Talc, dry flavor) Mixing Drying Compression
12
Sustained Release Tablets Therapeutic Range Minimum Effective Level Time Toxic level Drug Concentration (units mL-1) “Ideal” sustained blood or tissue drug level versus time profile
13
Toxic level Minimum Effective Level Drug Concentration (units mL-1) Time Repetitive release approach to sustained-release.
14
Pores produces by soluble portion of polymer membrane Membrane Reservoir Mechanism of Sustained Release : Diffusion Diffusion control of drug release by a water-insoluble polymer (left) Diffusion control of drug release by a Partially water-soluble polymer (right)
15
Mechanism of Sustained release: Dissolution
16
Mechanism of Sustained Release : Osmosis
Apresentações semelhantes
© 2024 SlidePlayer.com.br Inc.
All rights reserved.